EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis

Jia Deng, Ziyue Liao, Jian Gao

Current Oncology · 2023

DOI: 10.3390/curroncol30010096 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Current Oncology, 2023. Verfasst von Jia Deng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Second Clinical College, Chongqing Medical University, Chongqing 400000, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Thrombosis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) may enhance the efficacy of treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT); however, it remains unclear. We aim to evaluate the efficacy of TACE combined with TKIs.

Methods

A thorough literature search was performed on major databases since their inception until October 2022. Based on the eligibility criteria, eight studies (2103 patients) were included.

Results

Meta-analysis showed that TACE+sorafenib/apatinib had a better tumor response (objective response rate (ORR): RR = 4.85, 95% CI 2.68–8.75, disease control rate (DCR): RR = 3.23, 95% CI 1.88–5.56), and prolonged OS (HR = 0.50, 95%CI 0.42–0.60, p < 0.00001) than TACE alone. TACE+lenvatinib was stronger than TACE+sorafenib in ORR (60.7% vs. 38.9%) and TTP (HR = 0.61, 95% CI 0.43–0.86), whereas it was similar in DCR (96.4% vs. 96.3%) and OS (HR = 0.70 95% CI 0.46–1.05).

Conclusions

TACE plus sorafenib or apatinib was superior to TACE alone for hepatocellular carcinoma with PVTT; no significant advantage was found between TACE+lenvatinib and TACE+sorafenib, although TACE+lenvatinib performed better in terms of ORR and TTP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticThrombosisHumansSorafenibTyrosine Kinase InhibitorsPortal VeinTreatment OutcomePhenylurea CompoundsQuinolines

Stichwörter der Autor:innen

hepatocellular neoplasm (HCC)meta-analysisportal vein tumor thrombus (PVTT)transcatheter chemoembolization (TACE)tyrosine kinase inhibitor (TKI)

Substanzen

SorafenibTyrosine Kinase InhibitorslenvatinibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Second Clinical College, Chongqing Medical University, Chongqing 400000, China.
  • Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400000, China.

Zitieren

APA

Deng, J., Liao, Z., & Gao, J. (2023). Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. Current Oncology. https://doi.org/10.3390/curroncol30010096

Vancouver

Deng J, Liao Z, Gao J. Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. Current Oncology. 2023. doi:10.3390/curroncol30010096

BibTeX
@article{Deng2023,
  author = {Deng, Jia and Liao, Ziyue and Gao, Jian},
  title = {Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30010096}
}
Kostenlos starten →